1
|
Day JW, Finkel RS, Mercuri E, Swoboda KJ, Menier M, van Olden R, Tauscher-Wisniewski S, Mendell JR. Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec. Mol Ther Methods Clin Dev 2021; 21:76-82. [PMID: 33768131 PMCID: PMC7973120 DOI: 10.1016/j.omtm.2021.02.014] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Accepted: 02/19/2021] [Indexed: 12/26/2022]
Abstract
Spinal muscular atrophy is a progressive, recessively inherited monogenic neurologic disease, the genetic root cause of which is the absence of a functional survival motor neuron 1 gene. Onasemnogene abeparvovec (formerly AVXS-101) is an adeno-associated virus serotype 9 vector-based gene therapy that delivers a fully functional copy of the human survival motor neuron gene. We report anti-adeno-associated virus serotype 9 antibody titers for patients with spinal muscular atrophy when they were screened for eligibility in the onasemnogene abeparvovec clinical trials (intravenous and intrathecal administration) and managed access programs (intravenous). Through December 31, 2019, 196 patients and 155 biologic mothers were screened for anti-adeno-associated virus serotype 9 binding antibodies with an enzyme-linked immunosorbent assay. Of these, 15 patients (7.7%) and 23 biologic mothers (14.8%) had titers >1:50 on their initial screening tests. Eleven patients (5.6%) had elevated titers on their final screening tests. The low percentage of patients with exclusionary antibody titers indicates that most infants with spinal muscular atrophy type 1 should be able to receive onasemnogene abeparvovec. Retesting may identify patients whose antibody titers later decrease to below the threshold for treatment, and retesting should be considered for patients with anti-adeno-associated virus serotype 9 antibody titers >1:50.
Collapse
Affiliation(s)
- John W. Day
- Division of Neuromuscular Medicine, Stanford Neuroscience Health Center, MC 5979, 213 Quarry Road, Palo Alto, CA 94304, USA
| | - Richard S. Finkel
- Center for Experimental Neurotherapeutics, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
- Department of Pediatrics, Nemours Children’s Hospital, Orlando, FL, USA
| | - Eugenio Mercuri
- Department of Paediatric Neurology and Nemo Clinical Centre, Catholic University, Largo Agostino Gemelli 8, 00168 Rome, Italy
| | - Kathryn J. Swoboda
- Department of Neurology, Massachusetts General Hospital for Children, 185 Cambridge Street no. 5-240, Boston, MA 02114, USA
| | - Melissa Menier
- Novartis Gene Therapies, Inc., 2275 Half Day Road, Suite 200, Bannockburn, IL 60015, USA
| | - Rudolf van Olden
- Novartis Gene Therapies, Inc., 2275 Half Day Road, Suite 200, Bannockburn, IL 60015, USA
| | | | - Jerry R. Mendell
- Center for Gene Therapy, Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, OH 43205, USA
- Departments of Pediatrics and Neurology, The Ohio State University, 410 West 10th Avenue, Columbus, OH 43210, USA
- Corresponding author: Jerry R. Mendell, MD, Center for Gene Therapy, Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, OH 43205, USA.
| |
Collapse
|